Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 8:52 p.m.

    📋 Neoleukin Therapeutics Inc (was merged wih Neurogene (NASDAQ: NGNE) on 19/12/23) (NLTX) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:00:59

    Event Type: Clinical Trial Update

    Event Details:

    Neoleukin Therapeutics Inc (was merged wih Neurogene (NASDAQ: NGNE) on 19/12/23) (NLTX) Announces Clinical Trial Update Neoleukin Therapeutics Inc (was merged wih Neurogene (NASDAQ: NGNE) on 19/12/23) (NLTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Milestones, data
    • Diseases/Conditions: our Phase 1/2 trial, Rett syndrome
    • Clinical Stage: Phase 1
    • Collaboration: Phase 1/2
      • anticipated in 2026
      • expected in second quarter of 2026

    🔬 Clinical Development Pipeline (Neoleukin Therapeutics Inc (was merged wih Neurogene (NASDAQ: NGNE) on 19/12/23)):

    Product Type Development Stage Therapeutic Area Source
    NGN-401 GENETIC Phase PHASE3 Rett Syndrome ClinicalTrials.gov
    Sham OTHER Phase PHASE2 Geographic Atrophy (GA) ClinicalTrials.gov
    Avacincaptad Pegol intravitreal solution DRUG Phase PHASE2 Geographic Atrophy (GA) ClinicalTrials.gov
    ONL1204 Opthalmic solution DRUG Phase PHASE2 Geographic Atrophy (GA) ClinicalTrials.gov
    NGN-101 GENETIC Phase PHASE1 Neuronal Ceroid Lipofuscinosis CLN5 ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Neoleukin Therapeutics Inc (was merged wih Neurogene (NASDAQ: NGNE) on 19/12/23)
    • Ticker Symbol: NLTX

Search

News categories